GLV EXAM NITRILE FLEXAL COMFORT MD

Additional Manufacturer Narrative

<P CLASS="">FROM THE DEVICE HISTORY RECORD, LOT NUMBER 12P19A031 WAS MANUFACTURED IN JAN 2019. ALL THE INCOMING RAW MATERIALS, IN-PROCESS QUALITY ASSURANCE INSPECTION AND FINAL INSPECTIONS HAVE BEEN COMPLETED. AS PER INVESTIGATION, IN-PROCESS QUALITY ASSURANCE (IPQA) AND PRE-SHIPMENT QUALITY ASSURANCE (PSQA) HAVE PERFORMED THE BUY OFF INSPECTION PROCESS AND PASSED WITHIN THE SPECIFICATION LIMITS BASED ON THE RANDOM SAMPLING PLAN. NO DEVIATION WAS RAISED ON THE INCOMING, IN-PROCESS OR FINAL STAGES OF THE PRODUCT.</P> <P CLASS="">ONE OPEN INNER OF SAMPLE RETURNED FOR INVESTIGATION. THE SAMPLE WAS SENT OUT TO AN EXTERNAL LAB FOR TESTING. THE PRIMARY SKIN IRRITATION TEST SHOWS THAT THERE WAS NO OBSERVABLE IRREVERSIBLE ALTERATION ON THE SKIN AT THE SITES OF CONTACT WITH THE TEST MATERIAL. THE CHEMICAL RESIDUES TEST RESULTS SHOWS THAT NO DETECTION OF THE CHEMICALS RESIDUES THAT COULD CAUSE AN ALLERGIC REACTION.</P> <P CLASS="">THERE WERE NO CHANGES IN THE PROCESS, PRODUCTION, MACHINE, AND RAW MATERIALS USED DURING THE MANUFACTURING PROCESS. ADDITIONALLY, THE GLOVES HAVE BEEN TESTED THROUGH DERMAL SENSITIZATION TEST AND PRIMARY SKIN IRRITATION TEST. HOWEVER, THERE WERE NOT ANY ABNORMALITIES OBSERVED DURING THE TEST PERFORMED.</P> <P CLASS="">THE OPERATING PARAMETERS WERE WITHIN THE VALIDATION RANGE. THE PRE-LEACHING AND POST-LEACHING READING FOR ALL RIPPING MACHINE INVOLVED WERE WELL WITHIN THE SPECIFICATION. THE PRE-SHIPMENT INSPECTION RESULTS INDICATED THAT THE PRODUCT UNDER THE LOT NUMBER HAS MET THE SPECIFIED REQUIREMENT PER PRODUCT SPECIFICATION AND RELEASE CRITERIA BEFORE RELEASED FOR SHIPMENT. FROM THE INVESTIGATION, THE ROOT CAUSE COULD NOT BE DETERMINED. WE WILL CONTINUE MONITORING CUSTOMER COMPLAINTS FOR TRENDS, WHICH MAY REQUIRE FURTHER INVESTIGATION.</P>;;.

Additional Manufacturer Narrative

THE SAMPLE WAS RECEIVED BY CARDINAL HEALTH PLANT ON 9/24/2020. THE SAMPLE WAS FORWARDED TO THE GLOVE SUPPLIER AND WAS SENT OUT TO AN EXTERNAL LAB FOR TESTING. THE TESTING CAN TAKE UP TO 3 MONTHS. A FOLLOW-UP WILL BE SENT ONCE TESTING EVALUATION IS RECEIVED BACK TO CARDINAL HEALTH.

Additional Manufacturer Narrative

FROM THE DEVICE HISTORY RECORD, LOT NUMBER 12P19A031 WAS MANUFACTURED IN JAN 2019. ALL THE INCOMING RAW MATERIALS, IN-PROCESS QUALITY ASSURANCE (QA) INSPECTION AND FINAL INSPECTIONS HAVE BEEN COMPLETED. AS PER INVESTIGATION, IN-PROCESS QA (IPQA) AND PRE-SHIPMENT QA (PSQA) HAVE PERFORMED THE BUY OFF INSPECTION PROCESS AND PASSED WITHIN THE SPECIFICATION LIMITS BASED ON THE RANDOM SAMPLING PLAN. NO DEVIATION WAS RAISED ON THE INCOMING, IN-PROCESS OR FINAL STAGES OF THE PRODUCT. NO SAMPLE RETURNED FOR INVESTIGATION. THERE WERE NO CHANGES IN THE PROCESS, PRODUCTION, MACHINE, AND RAW MATERIALS USED DURING THE MANUFACTURING PROCESS. ADDITIONALLY, THE GLOVES HAVE BEEN TESTED THROUGH DERMAL SENSITIZATION TEST AND PRIMARY SKIN IRRITATION TEST. THERE WERE NO ANY ABNORMALITIES OBSERVED DURING THE TEST PERFORMED. THE OPERATING PARAMETERS WERE WITHIN THE VALIDATION RANGE. THE PRE-LEACHING AND POST-LEACHING TDS READING FOR ALL RIPPING MACHINE INVOLVED WERE WELL WITHIN THE SPECIFICATION. BESIDES, THE PRE-SHIPMENT INSPECTION RESULTS INDICATED THAT THE PRODUCT UNDER THE LOT NUMBER HAS MET THE SPECIFIED REQUIREMENT PER PRODUCT SPECIFICATION AND RELEASE CRITERIA BEFORE RELEASED FOR SHIPMENT. FROM THE INVESTIGATION, THE ROOT CAUSE COULD NOT BE DETERMINED. THEREFORE, NO ACTION WILL BE TAKEN AT THIS TIME, WE WILL CONTINUE MONITORING OUR CUSTOMER COMPLAINTS DATA BASE FOR THIS AND ANY OTHER ISSUES REPORTED OF THE SAME NATURE.

Description of Event or Problem

BASED ON INFORMATION RECEIVED FROM THE CUSTOMER ALLEGEDLY THE EMPLOYEES¿ HANDS ARE BREAKING OUT DUE TO USING THE GLOVES. THE EMPLOYEE WAS REPORTEDLY SEEN BY HER PHYSICIAN AND PRESCRIBED TRANSDERMAL STEROID CREAM.